SCHEMBL20046743

SCHEMBL20046743

O=C1C(NCCO)=C(C2=C(NCCO)C(=O)c3cc(F)ccc3C2=O)C(=O)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 4/20 0.55
MAPT P10636 5/20 0.49
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 5/20 0.49
GAA P10253 4/20 0.49
MAPK1 P28482 4/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CASP6 P55212 2/20 0.49
LMNA P02545 4/20 0.49
APAF1 O14727 3/20 0.49
TDP2 O95551 2/20 0.49
CASP3 P42574 2/20 0.49
SENP8 Q96LD8 2/20 0.49
SENP7 Q9BQF6 2/20 0.49
SENP6 Q9GZR1 2/20 0.49
THRB P10828 1/20 0.46
HTT P42858 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20046780 0.87 CDC25A (0.70) CDC25AMAPTKDM4EALDH1A1GAA
SCHEMBL20046782 0.80 MAPT (0.65) CDC25AMAPTKDM4EALDH1A1GAA
SCHEMBL20046774 0.78 CDC25A (0.77) CDC25AMAPTKDM4EALDH1A1GAA
SCHEMBL3894758 0.73 MEN1 (0.57) MAPTKDM4EALDH1A1MAPK1L3MBTL1
SCHEMBL20046820 0.72 CDC25A (0.51) CDC25AMAPTKDM4EALDH1A1GAA
SCHEMBL17249976 0.71 CDC25A (1.00) CDC25AMAPTKDM4EALDH1A1GAA
SCHEMBL181722 0.71 PTPRC (0.55) MAPTKDM4EALDH1A1MAPK1L3MBTL1
SCHEMBL30886642 0.71 PTPRC (0.60) MAPTKDM4EALDH1A1MAPK1L3MBTL1
SCHEMBL29390818 0.71 PTPRC (0.55) MAPTKDM4EALDH1A1MAPK1L3MBTL1
SCHEMBL13487409 0.71 PTPRC (0.60) MAPTKDM4EALDH1A1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200283417-A1 AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA UNIVERSITY OF MARYLAND, BALTIMORE 2020-09-10 US disclosed
WO-2018067842-A1 AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA UNIVERSITY OF MARYLAND, BALTIMORE (US) 2018-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283417-A1 AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA MCL1, NPM1, ABL1 CDC25A 938/4885MAPT 4723/4885KDM4E 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.